Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Sanofi Stories

2014-02-28 08:25:23

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq(®), which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of...

2014-02-19 08:31:31

Talks by Holopack and Sanofi will highlight innovative software solutions supporting environmental monitoring and externalized collaboration; Accelrys to address mobile initiatives in the lab SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced that it is sponsoring four talks at the 9th Annual SmartLab Exchange to be held on February 25-26 in Munich. As Europe's premier...

2014-02-12 12:30:26

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Brazilian Pharmaceutical Market 2014-2024Report DetailsDrug selling in Brazil - this new analysis shows you trends, opportunities, and revenuesDo you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.So...

2014-02-11 08:30:49

- Fourth quarter 2013 EYLEA® (aflibercept) Injection global net sales were $586 million, consisting of $402 million in the U.S. and $184 million in rest of world(1) TARRYTOWN, N.Y., Feb. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2013 and provided an update on development programs....

2014-02-06 08:27:40

PARIS, Feb. 6, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2013 Change (reported) Change (CER) 2013 Change (reported) Change (CER) Net sales EUR8,457m -0.8% +6.5% EUR32,951m -5.7% -0.5% Business net income(1) EUR1,810m...

2014-02-05 08:29:22

Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced today that Frederic Chereau has joined aTyr as president and chief operating officer. Mr. Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme. Mr. Chereau's appointment will...

2014-02-05 08:29:18

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept- LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS) announced today that it has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis...

2014-02-04 12:28:20

First and only medicine in its class approved for over-the-counter use that provides 24 hour relief of the full range of nasal allergy symptoms including nasal congestion BRIDGEWATER, N.J., Feb. 4, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its U.S. consumer healthcare division Chattem announced today that Nasacort(®) Allergy 24HR Nasal Spray is now available over-the-counter (OTC) in the U.S. to relieve the full range of seasonal and year-round nasal allergy...

2014-01-28 08:29:50

PLANTATION, Fla., Jan. 28, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer. Dr. Richard Scheyer Dr. Richard Scheyer has 30 years of...

2014-01-15 08:29:16

NEW DELHI, January 15, 2014 /PRNewswire/ -- - Cold and Cough remedies has conventionally remained the leading segment of the industry with a value share of 24.9% of the total sales as of 2012 - The vitamins and mineral supplements sales value have increased predominantly over the years from USD 873.9 million in 2006 to USD 1,091.9 million in 2012 - Slovakia has emerged as the fastest growing market for OTC drugs in the region...